

Original Article

Title: Serious adverse events reported from the COVID-19 vaccines: A descriptive study based on WHO database

Short title: Serious adverse events with COVID-19 vaccines

Author Affiliations:

1. Siddhartha Dutta, Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India. Email: siddhartha.dutta87@gmail.com, Orcid ID: <https://orcid.org/0000-0001-6525-5950>
2. Rimple Jeet Kaur, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India. Email: sidhurimple@yahoo.com Orcid ID: <https://orcid.org/0000-0003-4478-1411>
3. Jaykaran Charan, Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India. Email: dr.jaykaran78@gmail.com Orcid ID: <https://orcid.org/0000-0002-4857-6725>
4. Pankaj Bhardwaj, Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India. Email: pankajbhardwajdr@gmail.com Orcid ID: <https://orcid.org/0000-0001-9960-3060>
5. Praveen Sharma, Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India. Email: praveensharma55@gmail.com Orcid ID: <https://orcid.org/0000-0002-8324-737X>
6. Sneha Ambwani, Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India. Email: sr_ambwani@yahoo.com Orcid ID: <https://orcid.org/0000-0003-3304-2808>
7. Mainul Haque, Professor of the Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, 57000 Kuala Lumpur, Malaysia. Email: runurono@gmail.com. Orcid ID: <https://orcid.org/0000-0002-6124-7993>
8. Ankita Tandon, Department of Oral Pathology, Microbiology and Forensic Odontology, Dental Institute, Rajendra Institute of Medical Sciences, Ranchi-834009, India. Email: drankitatandon7@gmail.com Orcid ID: <https://orcid.org/0000-0002-7527-0772>

9. Jha Pallavi Abhayanand, Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India. Email: pallavijhap06@gmail.com Orcid ID: <https://orcid.org/0000-0002-6936-3315>

10. Sanchi Sukhija, Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India. Email: sanchisukh7@gmail.com Orcid ID: <https://orcid.org/0000-0003-3549-2669>

11. Suman S V, Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India. Email: sumanmra@gmail.com Orcid ID: <https://orcid.org/0000-0003-3469-2853>

12. Sanjeev Misra. The Director and CEO, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India. Email: misralko@gmail.com Orcid ID: <https://orcid.org/0000-0002-0641-0946>

Corresponding Author

Jaykaran Charan, Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India. Email: dr.jaykaran78@gmail.com Orcid ID: <https://orcid.org/0000-0002-4857-6725>

Abstract:

Background: In the light of current pandemic, the emergency approval of few COVID-19 vaccines seems to provide a ray of hope. However, their approval is solely based on limited data available from the clinical trials in a short period of time; thereby imposing a necessity to study the adverse events(AEs) associated with their use. This study therefore aims to assess the Serious Adverse Events (SAEs) associated with various COVID-19 vaccines reported in the WHO database (VigiBase®).

Methods: The data from VigiBase® was analyzed to assess the reported SAEs linked to various COVID-19 vaccines. The duplicates in the data were removed and were analyzed on the basis of age, gender, and seriousness of adverse events at the System Organ Classification (SOC) level and the individual Preferred Term (PT) level.

Results: A total 103954 adverse events reported from 32044 subjects were taken for analysis. Of 32044 subjects, majority were females (80%). Also, a total of 28799 (27.7%) SAEs were reported from the 8007 individuals. Most of the SAEs were observed in Europe (83%) amongst females (79.4%) between 18 to 64 years (80.74%) of age. Majority of SAEs (74%) were reported for BNT162b2 (Pfizer) vaccine. On system wise classification, general disorders (30%) were the commonest followed by nervous system (19.1%) and musculoskeletal (11.2%) disorders. In individual category, headache (8.1%) was the commonest, followed by pyrexia (7%) and fatigue (5.1%). The number of SAEs were reported with various vaccines were comparatively lesser as compared to the non-serious ones and incidence of death was low with all the vaccines candidates. Elderly (> 65 years) people reported more serious AEFIs as compared to other age groups.

Conclusion: The reported SAEs from the COVID–19 vaccines were in line with the data published in clinical trials. To link these SAEs to vaccines will need causality analysis and review of individual reports.

Keywords: COVID-19 Vaccine; COVID-19; SARS-COV2; Adverse Events; VigiBase®

Introduction

The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has enveloped the entire globe with serious impositions on almost every phase of human life.^{1,2} The World Health Organization (WHO) reported approximately 99,864,391 cases of COVID-19 alongside surmounting to nearly 2,149,700 deaths by January 27th, 2021.³ The rapid upsurge in active COVID-19 cases produced a major health care crisis due to lack of alertness to confront a sudden pandemic especially in developing nations.⁴ However, in accordance with the present situation, there has been a downward trend in the number of COVID-19 cases as reported by WHO.⁵

At the onset, the disease had multifaceted spectrum with no effective medication, hence hit and trial strategy with older drugs was implanted in order to find an answer to this morbid disease.⁶ However a lot of therapies were being tried and are still under clinical trials to prove their efficacy yet infection control measures, sanitation, symptomatic and supportive therapy has been the cornerstone of effective clinical management of the COVID-19.^{6,7} Later, Food and Drug Administration (FDA) approved Remdesivir for the treatment of COVID-19.⁸

As there was no definitive therapy in conjunction with a tremendous rise in the number of cases, an effective vaccine vestiges the only answer in building immunity in order to bring a halt to further progression of the disease.⁹ As of Jan 26, 2021, WHO in its “COVID-19 - Landscape of novel coronavirus candidate vaccine development worldwide” document reported a total of 236 vaccine candidates under development and of which 63 were in clinical trial phase and 173 were under preclinical development.¹⁰ The vaccines that are in clinical development are mostly protein subunit vaccine, Viral Vector (non-replicating), DNA, Inactivated Virus and RNA vaccines.¹⁰ With most of the trials underway and few clearing phase 3 studies, the pharmaceutical industries applied for

the Emergency Use Authorization (EUA) of few vaccines. As of January 29, 2021 there were a total of nine vaccines which have been approved around the world namely Comirnaty (BNT162b2), Moderna COVID-19 Vaccine (mRNA-1273), CoronaVac, COVID-19 Vaccine AstraZeneca (AZD1222), vaccine from Sinopharm and the Wuhan Institute of Virology, Sputnik V, BBIBP-CorV, EpiVacCorona and Covaxin.¹¹ The FDA on Dec 11, 2020 gave EUA to the Pfizer-BioNTech vaccine for COVID-19 to be distributed in the United States of America for individuals having age 16 years of and older.¹² Later by Dec 18, 2020 FDA also approved Moderna vaccine for COVID-19 for use for in individuals 18 years of age and older.¹³ However, FDA emphasized that EUA is only based on limited efficacy safety data and it is not full approval of the vaccine.^{12, 13} In India, two vaccines namely Covishield from Serum Institute of India and Covaxin from Bharat Biotech received Restricted Emergency Approval for prevention of COVID-19.¹⁴ Although these vaccines have been granted approval for emergency use, their long term efficacy is yet to be established.

It is extremely critical to monitor the vaccine safety and/or SAEs using Pharmacovigilance which is defined as “the science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other drug related problem”.¹⁵ Pharmacovigilance is an essential component while using any medical or paramedical modalities for patient care and safety as monitoring adverse effects of drugs, vaccines and other interventions would help identify the safer drugs, preventing patients from unnecessary harms and reducing the hospitalization and treatment cost hence assuring rational use of medications and interventions.¹⁶ For strict pharmacovigilance WHO authorizes and maintains global database of AEFIs through VigiBase® which maintains the global safety data of various therapeutic interventions as Individual Case Safety Reports (ICSRs).¹⁷ It came into existence in 1968 and consists of over 20 million ICSR

from over 130 countries. ICSRs are also known as the spontaneous or voluntary reports which are generated in the post marketing phase of the drug. Each ICSR contains the information regarding patient's demographics; drugs; adverse events and administrative information.^{17, 18}

This descriptive analysis is an extension to the studies conducted using same database on drugs used in COVID-19 therapeutics including Favipiravir and Remdesivir.^{19, 20} This descriptive study aims to identify and describe various SAEs reported for the COVID – 19 vaccines through WHO database thereby facilitating identification of safer vaccines, preventing patients from unnecessary tribulations and reducing the hospitalization and treatment costs in order to assure rational vaccination regimens and strategies.

Methodology:

Data Source:

Data for this study was obtained from the VigiBase®, which is a database maintained by WHO Uppsala monitoring center (UMC), Uppsala, Sweden. All vaccine safety data reported from 15th December 2020 to 24th January 2021 were obtained in excel format from the UMC. Data were cleaned from duplicates and irrelevant entries by the first and second author (SD, RK) and any discrepancy for removal or retention of data for analysis was resolved by discussion and consensus in the presence of corresponding author (JC). This database has all the data reported in the form of adverse drug events associated with COVID-19 vaccines using Individual Case Safety Reports (ICSRs).¹⁷ The detailed information regarding patient's demographics (age, gender, country, medical history); drugs (indication of use, route of administration, start and end date); adverse events (date of onset, seriousness, outcome, dechallenge and rechallenge outcomes. and causality) and administrative information (type and source of report) was recorded.^{17, 21}

Data interpretation and analysis:

Each report in VigiBase® represents an individual Adverse Events (AEs) and there could be more than one report for a single individual thus the number of reported AEs were more than the number of individuals who actually had adverse event. Hence, the data was cleaned manually to remove the duplicates in the form of same adverse events reported for same individual in different terminologies.

All the adverse drug reactions in the ICSR are automatically coded as per MedDRA (Medical Dictionary for Regulatory Activities) and WHO-ART terminology.^{17,21} MedDRA is the hierarchical terminology that is composed of five levels: Lowest Level Terms (LLTs), Preferred Term (PTs), High Level Group Terms (HLGTs), High–Level Terms (HLT) and SOCs (System Organ Classification).^{22, 23}

In the present study, the SOC and PT categories of AEs were only employed for the analysis. Here PT refers to clinical condition in the form of symptom, sign, diagnosis, investigation, medical, social or family history and characteristic surgical or medical procedures.²³ Each PT is linked to specific SOC which is grouping by manifestation site (eg. Cardiovascular disorder), aetiology (infections and infestations) and purpose (surgical and medical procedures).²⁴ The age, gender and severity of all the adverse events were compared with the SOC and PT. The seriousness of the adverse event was decided as per the ICH E2B criteria which identifies SAEs as those leading to either life threatening event, hospitalization, disability, congenital abnormality or death.²⁵

Ethical Approval:

This study had no direct interaction with human participants and was based on the WHO's database (VigiBase®) hence, the ethical approval was not required.

Statistical Analysis:

Descriptive statistics were reported in the form of frequency and percentages. Cross tabulation function of Statistical Package for Social Science version 17 was used for the analysis.

Results

A total 103954 AEs were reported till 24th Jan 2021 from 32044 subjects (Average 3.24 AEs per person). Out of the total subjects, 5731 (17.9%) were males and 25652 (80 %) were females. A total of 28799 (27.7%) AEs from 8007 individuals were categorized as Serious Adverse Events (SAEs) (**Figure 1**). Majority of SAEs were reported in females and between the age group of 18 to 64 years. Around 83% of the SAEs were reported from European countries(N=23987) followed by Americas(N=4795) and Asia(N=17) (**Figure 2**). In almost 74% of cases the BNT162b2 (Pfizer) vaccine was used. Around 1% of SAEs were fatal (**Table 1**).

Majority of the SAEs were reported from the broad category “general disorders and administration site conditions” (30%), followed by “Nervous system disorders” (19.1%), “Musculoskeletal and connective tissue disorders” (11.2%) and “Gastrointestinal disorders” (10.7%) (**Table 2**).

Upon analyzing the Preferred Terms (PTs) in the broad categories, 28799 SAEs were reported. Headache (8.11%) of various types were most common SAEs followed by pyrexia (7.09%), fatigue (5.18%), nausea (4.4%), chills (4.2%) and myalgia (3.9%). Pain (1.93 %), pain in extremity (1.98 %) and vaccination site /injection site/administration site pain (1.88) accounted for another major portion of SAEs (**Table 3**).

Table 4 describes the distribution of serious and non-serious AEs between type of vaccines, gender and age groups. The comparison of serious vs. non serious AEs with various vaccine candidates shows the probability of serious AEs are comparatively low as compared to the non-serious AEs.

Age group > 65 years had more serious AEs as compared to other age groups. There was equal distribution of serious and non-serious AEs between males and females.

There were a total 424 deaths. Distribution of these deaths as per the vaccines, gender and age group have been mentioned in the **Table 5**.

Discussion

The present study was conducted to assess the SAEs reported in the global pharmacovigilance database (VigiBase®) associated with various COVID-19 vaccines like BNT162b2(Pfizer), AZD1222/ChAdOx1 nCoV-19(AstraZeneca), Moderna etc. that are currently being used across the world for vaccination. Approximately one third of the total AEs reported were serious in nature. The majority of the AEs reported were from the female subjects and from age group 18 to 64 years. A major chunk of AEs was reported from Europe and in majority of the cases BNT162b2(Pfizer) vaccine was used. Most commonly the AEs reported were classified under general disorders and administration side conditions with headache, fever and fatigue as the commonest AEs observed.

In the current analysis, the ratio of serious and non-serious AEs was similar amongst males and females but overall, more numbers were reported from females. Centres for Disease Control and Prevention(CDC) in their Morbidity and Mortality Weekly Report (MMWR) reported that after first dose of Pfizer-BioNTech COVID-19 Vaccine almost 90 % of the anaphylactic reactions and non-anaphylactic allergic reactions were observed in females among which 81% of them with anaphylaxis and 67% with non-anaphylactic allergic reactions had a history of allergic reactions.^{26,27} However in the above report, about 62% of the Pfizer-BioNTech COVID-19 vaccines were received by females which can be a reason for preponderance of allergic reactions in females.²⁶ Similar report by CDC on the Moderna COVID-19 Vaccine reported that about 61%

of the vaccine recipients were females and almost 100% of the anaphylactic reaction and 91% of non-anaphylactic allergic reactions were observed in females amongst which 90% of them with anaphylaxis and 60% with non-anaphylactic allergic reactions had a history of allergic reactions.²⁸

The proportion of female population in United States was 50.51% and in Europe it was 51.12 % in 2019.^{29, 30} WHO in its 'Health Workforce Working paper 1' compared the percentage of male and female health care professionals(HCPs) in Europe and America in 2019 and the percentage of female physicians in USA was 46% but was 53% in Europe whereas the percentage of nursing workforce was specifically dominated by females which was 86% in USA and 53% in Europe.³¹ So the more AEs reported in females could be attributed to a greater number of females as health workers. The During the early roll out of the vaccine, it was preferably given to the Health Care Professionals (HCPs) and the above data shows a female predominance in the HCPs hence more female HCPs might have received the vaccine as compared to the male ones which could be a reason for the more number AEs reported by the females. However, the difference in the reporting is too skewed to be justified only on the basis of this reason.

Study conducted by Harris T et al on assessing the gender-specific differences in AEs reporting with various vaccines in Ontario during 2012-2015 reported that the most of the AEs reported (66.2%) were associated with females.³² However, there was a more even distribution observed while analysing the SAEs of either gender (57.5% female, RRR 1.3).³² Literature reveals that previous studies done by Huang et al (63%) on MF59®-adjuvanted H5N1 influenza vaccine and Halsey et al on H1N1 vaccines reported female predominance in the AEs associated with the respective vaccinations.^{33, 34} A review conducted by Fink et al on impact of gender and response to vaccines in elderly reported that the AEs with females as compared to males were consistently

higher with response to various vaccines like influenza, pneumococcal, herpes zoster, tetanus and pertussis.³⁵⁻⁴¹ The reactions observed by the either gender were similar but female vaccine recipients reported more local reactions, like injection site pain, redness, and swelling, as well as some of the systemic reactions like joint pain, myalgia, headache, back pain, abdominal pain, fever, chills, and hypersensitivity reactions.^{35, 41} Few probable explanations in favour of females with higher number of AEs can be due to increased humoral and cell-mediated immune reactions to antigens, vaccine, and infections as compared to males.^{42, 43}

The SAEs with the Pfizer-BioNTech COVID-19 Vaccine from their clinical trial experience in the 16 to 55 years of age were reported by 0.4% of the recipients and 0.8% of the participants with more than 56 years of age and older.⁴⁴ In the present analysis, the SAEs constituted of 25.23% of the total AEs reported in the Vigibase and deaths were observed in 0.40% of total SAEs associated with Pfizer-BioNTech vaccine. Whereas, as per the data reported from clinical trials, death was reported in two (0.01%) vaccine recipients and both of them were above 55 years of age.^{44, 45} The proportion of non-fatal SAEs was 0.6% with the vaccine and most common AEs reported were appendicitis (0.04%), acute myocardial infarction (0.02%), and cerebrovascular accident (0.02%).⁴⁴

As per the clinical trial experience of Moderna COVID-19 Vaccine, the proportion of vaccine recipients who developed at least one AEs was 1%. In our analysis the SAEs constituted of 26.73% of the total AEs reported in the Vigibase and death was observed in 1.23% of total SAEs associated with Moderna vaccine. As per the data reported to FDA there were six deaths reported after vaccination and most of them were above 70 years of age and associated co-morbid conditions. In the vaccine recipient group, the commonest SAEs reported were myocardial

infarction (0.03%), cholecystitis (0.02%), and nephrolithiasis (0.02%). As per the opinion of FDA, three SAEs were also considered to be likely caused by the vaccines which were one case of intractable nausea/vomiting and two of facial swelling.^{46, 47} The discrepancy in the proportion of SAEs between our study and the one reported to the FDA could be due to the fact that we calculated the proportion out of total adverse events reported and not from the total patients vaccinated.

The AEs from the COVID-19 vaccine from AstraZeneca as reported to Medicines & Healthcare products Regulatory Agency (MHRA) were not classified as serious or non-serious but reported general disorders and administration site conditions like injection site reaction/pain, fatigue, headache and nausea to be commonest SAEs.⁴⁸ A recent study published based on an interim analysis of four clinical trials conducted in Brazil, South Africa, and UK has also reported that 79(0.7%) of whom received ChAdOx1 nCoV-19 suffered gastrointestinal disorders, injury, poisoning and procedural complications, infections/infestations and nervous system disorders.⁴⁹ In our analysis more serious adverse events were reported in older age group in comparison to the younger age groups, this warrant a cautious approach when administering vaccine to the old age group people in the form of longer follow up and watchful vigilance.

The data analyzed in this study has been adapted from VigiBase which is a WHO global database for individual case safety reports. The data is collected from several sources and the probability that the suspected adverse effect is drug-related is not the same in all cases. In the absence of proper reporting of other parameters and technical problems in causality assessment, it is not appropriate to attribute all of these events to vaccine hence in this paper we used the term adverse events and not the adverse drug reaction which is more definitely linked to the drug. The data presented in this study does not represent the opinion of the Uppsala Monitoring Centre or the WHO.

Conclusion

The present study that the pattern of AEs reported in the database was in sync with the reactogenicity of the vaccines. However, there is an urgent need of systematic analysis regarding different AEs reported in this study for the purpose of measuring causalities through proper review of reports and by generating data in primary studies.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding: This paper was not funded.

Acknowledgment: We want to acknowledge 'mapchart.net', a free service used for preparation of a map diagram for this study

Disclosure:

The authors declare that they do not have any financial involvement or affiliations with any organization, association, or entity directly or indirectly with the subject matter or materials presented in this article. This also includes honoraria, expert testimony, employment, ownership of stocks or options, patents or grants received or pending, or royalties.

References

1. The World Bank. The Global Economic Outlook During the COVID-19 Pandemic: A Changed World. Jan 28, 2021. Updated Jun 8, 2020. Accessed Jan 28, 2021. <https://www.worldbank.org/en/news/feature/2020/06/08/the-global-economic-outlook-during-the-covid-19-pandemic-a-changed-world>
2. Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. *Int J Surg* 2020;78:185-193. doi:10.1016/j.ijssu.2020.04.018
3. World Health Organisation. WHO Coronavirus Disease (COVID-19) Dashboard. Jan 28, 2021. Updated Jan 27, 2021. Accessed Jan 28, 2021. <https://covid19.who.int/>
4. Blumenthal D, Fowler EJ, Abrams M, Collins SR. Covid-19 - Implications for the Health Care System. *N Engl J Med*. 2020 Oct;383(15):1483-1488. doi:10.1056/NEJMsb2021088
5. World Health Organisation. Weekly epidemiological update - 27 January 2021. Jan 28, 2021. Updated Jan 27, 2021. Accessed Jan 28, 2021. <https://www.who.int/publications/m/item/weekly-epidemiological-update---27-january-2021>
6. World Health Organisation. Coronavirus disease (COVID-19): Are there treatments for COVID-19? Jan 29, 2021. Updated Oct 12, 2020. Accessed Jan 29, 2021. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19>
7. Centers for Disease Control and Prevention. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19. Jan 29, 2021. Updated Dec. 4, 2020. Accessed Jan 29, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html>
8. National Institutes of Health: COVID-19 Treatment Guidelines Panel. Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19. Jan 29, 2021. Updated

Nov 3, 2020. Accessed Jan 29, 2021. <https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/#:~:text=Remdesivir%20is%20the%20only%20Food,the%20treatment%20of%20COVID%2D19.>

9. Green DR. SARS-CoV2 vaccines: Slow is fast. *Sci Adv.* 2020 Jul 8;6(28):eabc7428. doi: 10.1126/sciadv.abc7428. PMID: 32923602; PMCID: PMC7455480.

10. World Health Organisation. Draft landscape and tracker of COVID-19 candidate vaccines. Jan 29, 2021. Updated Jan 26, 2021. Accessed Jan 29, 2021. <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>

11. Craven J. Regulatory Focus:COVID-19 vaccine tracker. Regulatory Affairs Professionals Society (RAPS). Jan 29, 2021. Updated Jan 28, 2021. Accessed Jan 29, 2021. <https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker>

12. Food and Drug Administration. FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine. Dec 29, 2021. Updated Dec 11, 2020. Accessed Jan 29, 2021. <https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19>

13. Food and Drug Administration. FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine. Jan 30, 2021. Updated Dec 18, 2020. Accessed Jan 30, 2021. [https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-](https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid-19)

[covid#:~:text=The%20FDA%20has%20determined%20that,effective%20in%20preventing%20COVID%2D19.](https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid-19#:~:text=The%20FDA%20has%20determined%20that,effective%20in%20preventing%20COVID%2D19.)

14. Press Information Bureau Government of India. Press Statement by the Drugs Controller General of India (DCGI) on Restricted Emergency approval of COVID-19 virus vaccine. Jan 29, 2021. Updated Jan 3, 2021. Accessed Jan 29, 2021. <https://vaccine.icmr.org.in/images/pdf/HFW-DCGI-authorisation-3rdJanuary.pdf>
15. World Health Organisation. Pharmacovigilance: Regulation and Prequalification. Jan 31, 2021. Accessed Jan 31, 2021. <https://www.who.int/teams/regulation-prequalification/pharmacovigilance>
16. Dutta S. Pharmacovigilance in India: Evolution and Change in Scenario in India. *Int. J. Sci. Res.* 2018;7: 976-978. DOI: 10.21275/ART20192070
17. Uppsala Monitoring Centre: WHO Programme for International Drug Monitoring. VigiBase. Accessed 10 Oct, 2020. <https://www.who-umc.org/vigibase/vigibase/>
18. Uppsala Monitoring Centre. VigiBase: signalling harm and pointing to safer use. Accessed 10 Feb 2021. <https://www.who-umc.org/vigibase/vigibase/vigibase-signalling-harm-and-pointing-to-safer-use/>
19. Kaur RJ, Charan J, Dutta S, et al. Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database. *Infect Drug Resist.* 2020;13:4427-4438. doi:10.2147/idr.S287934
20. Charan J, Kaur RJ, Bhardwaj P, et al. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. *Expert Rev. Clin. Pharmacol.* 2021;14(1):95-103. doi:10.1080/17512433.2021.1856655
21. Uppsala Monitoring Centre: WHO Programme for International Drug Monitoring. VigiBase FAQs. Updated Mar 16, 2020. Accessed Mar 7, 2021. <https://www.who-umc.org/vigibase/vigibase/know-more-about-vigibase/>

22. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities(MedDRA). Accessed 12 Feb, 2021. <https://www.meddra.org/how-to-use/support-documentation/english/welcome>
23. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). MedDRA Hierarchy. Accessed 28 Feb, 2021. <https://www.meddra.org/how-to-use/basics/hierarchy>
24. Bousquet C, Lagier G, Louët AL-L, Le Beller C, Venot A, Jaulent M-C. Appraisal of the MedDRA Conceptual Structure for Describing and Grouping Adverse Drug Reactions. *Drug Saf.* 2005;28(1):19-34. doi:10.2165/00002018-200528010-00002
25. International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. Maintenance Of The Ich Guideline On Clinical Safety Data Management : Data Elements For Transmission Of Individual Case Safety Reports E2B(R2). Accessed Mar 9, 2021. https://admin.ich.org/sites/default/files/inline-files/E2B_R2_Guideline.pdf
26. Centers for Disease Control and Prevention. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. *MMWR Morb Mortal Wkly Rep* 2021. Jan 15, 2021 70:46–51. doi:<http://dx.doi.org/10.15585/mmwr.mm7002e1>
27. Shimabukuro T, Nair N. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. *JAMA.* 2021;325(8):780-781. doi:10.1001/jama.2021.0600 %J JAMA
28. Centers for Disease Control and Prevention. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021:MMWR Morb Mortal Wkly Rep 2021. CDC COVID-19 Response Team;

Food and Drug Administration. 2021;70:125–129.

doi:<http://dx.doi.org/10.15585/mmwr.mm7004e1>

29. The World Bank. Population, female (% of total population) - United States. Accessed Mar 8, 2021. <https://data.worldbank.org/indicator/SP.POP.TOTL.FE.ZS?locations=US>

30. The World Bank. Population, female (% of total population) - European Union. Accessed Mar 8, 2021. <https://data.worldbank.org/indicator/SP.POP.TOTL.FE.ZS?locations=EU>

31. World Health Organization. Gender equity in the health workforce: Analysis of 104 countries. Health Workforce Working paper 1. Updated Mar 2019. Accessed Mar 8, 2021. <https://apps.who.int/iris/bitstream/handle/10665/311314/WHO-HIS-HWF-Gender-WP1-2019.1-eng.pdf>

32. Harris T, Nair J, Fediurek J, Deeks SL. Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012-15. *Vaccine* 2017;35(19):2600-2604. doi:10.1016/j.vaccine.2017.03.035

33. Huang W-T, Chang C-H, Peng M-C. Telephone monitoring of adverse events during an MF59®-adjuvanted H5N1 influenza vaccination campaign in Taiwan. *Hum Vaccin Immunother.* 2014;10(1):100-103. doi:10.4161/hv.26737

34. Halsey NA, Griffioen M, Dreskin SC, et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. *Vaccine.* 2013;31(51):6107-12. doi:10.1016/j.vaccine.2013.09.066

35. Fink AL, Klein SL. Sex and Gender Impact Immune Responses to Vaccines Among the Elderly. *Physiology* 2015;30(6):408-16. doi:10.1152/physiol.00035.2015

36. Bayas JM, Vilella A, Bertran MJ, et al. Immunogenicity and reactogenicity of the adult tetanus-diphtheria vaccine. How many doses are necessary? *Epidemiol. Infect.* 2001;127(3):451-60. doi:10.1017/s095026880100629x
37. Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW, Virella G. A population-based serologic survey of immunity to tetanus in the United States. *N Engl J Med.* 1995;332(12):761-766. doi:10.1056/nejm199503233321201
38. Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005-2009. *J. Infect.* 2015;70(2):178-86. doi:10.1016/j.jinf.2014.08.018
39. Cook IF, Pond D, Hartel G. Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. *Vaccine.* 2007;25(25):4767-4774. doi:10.1016/j.vaccine.2007.04.017
40. Engler RJ, Nelson MR, Klote MM, et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. *Arch Intern Med* 2008;168(22):2405-2414. doi:10.1001/archinternmed.2008.513
41. Beyer WE, Palache AM, Kerstens R, Masurel N. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. *Eur J Clin Microbiol Infect Dis* 1996;15(1):65-70. doi:10.1007/bf01586187
42. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. *Nat Rev Immunol* 2008;8(9):737-744. doi:10.1038/nri2394
43. Klein SL. Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. *Bioessays.* 2012;34(12):1050-1059. doi:10.1002/bies.201200099

44. FDA Briefing Document: Pfizer-BioNTech COVID-19 Vaccine. Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020. Accessed Mar 8, 2021. <https://www.fda.gov/media/144245/download>
45. Centers for Disease Control and Prevention. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine. Updated Dec 13, 2020. Accessed Mar 8, 2021. <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html>
46. FDA Briefing Document: Moderna COVID-19 Vaccine. Vaccines and Related Biological Products Advisory Committee Meeting December 17, 2020. Mar 9, 2021. Updated Dec 17, 2020. Accessed Mar 9, 2021. <https://www.fda.gov/media/144434/download>
47. Centers for Disease Control and Prevention. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine. Updated Dec 20, 2020. Accessed Mar 9, 2021. <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html>
48. Medicines & Healthcare products Regulatory Agency. Information for UK recipients on COVID 19 Vaccine AstraZeneca. Updated Feb 23, 2021. Accessed Mar 9, 2021. <https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-uk-recipients-on-covid-19-vaccine-astrazeneca>
49. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021;397(10269):99-111. doi:10.1016/s0140-6736(20)32661-1

Tables

Table 1: Characteristics of SAEs (28799 SAEs reported from 8007 Individuals) reported for COVID – 19 vaccines in WHO database (n = 28799)

Parameter	Frequency (%)	
Age	< 18 Years	265 (0.92)
	18 – 64 Years	23255 (80.74)
	≥ 65 Years	4077 (14.15)
	Not reported	1202 (4.17)
Gender	Female	22866 (79.4)
	Male	5361 (18.6)
	Not reported	572 (2)
Outcome	Fatal	334 (1.2)
	Not recovered/not resolved	6856 (23.8)
	Recovered/resolved	9454 (32.8)
	Recovered/resolved with sequelae	269 (0.9)
	Recovering/resolving	5363 (18.6)
	Unknown	3336 (11.6)
	Not reported	3187 (11.1)
Name of Vaccine	BNT162b2	21384 (74.3)
	AstraZeneca	5649 (19.6)

Parameter		Frequency (%)
	Moderna	1697 (5.9)
	Not specified	69 (0.2)
Notified by	Consumer/Non-Health Professional	13061 (45.4)
	Other Health Professionals	6250 (21.7)
	Physicians	4102 (14.2)
	Pharmacists	804 (2.8)
	Lawyer	1 (0.003)
	Not reported	4581 (15.9)

Table 2: Distribution of SAEs reported from the COVID – 19 vaccines as per the broad system-based classification (N=28779).

Adverse Events Broad Heading Categories	Frequency (%)
Blood and lymphatic system disorders	355 (1.23)
Cardiac disorders	710 (2.47)
Congenital, familial and genetic disorders	2 (0.01)
Ear and labyrinth disorders	191 (0.66)
Eye disorders	365 (1.27)
Gastrointestinal disorders	3103 (10.77)
General disorders and administration site conditions	8640 (30.0)
Hepatobiliary disorders	12 (0.04)
Immune system disorders	363 (1.26)
Infections and infestations	565 (1.96)
Injury, poisoning and procedural complications	82 (0.28)
Investigations	1006 (3.49)
Metabolism and nutrition disorders	234 (0.81)
Musculoskeletal and connective tissue disorders	3225 (11.20)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	3 (0.01)
Nervous system disorders	5502 (19.10)
Pregnancy, puerperium and perinatal conditions	17 (0.06)
Product issues	1 (0.003)

Psychiatric disorders	470 (1.63)
Renal and urinary disorders	83 (0.29)
Reproductive system and breast disorders	59 (0.20)
Respiratory, thoracic and mediastinal disorders	1709 (5.93)
Skin and subcutaneous tissue disorders	1500 (5.21)
Social circumstances	22 (0.08)
Surgical and medical procedures	20 (0.07)
Vascular disorders	560 (1.94)

Table 3: Common individual Adverse Events reported from the COVID – 19 vaccines.

Specific Adverse Events	Frequency (%)
Headache/ Tension headache/ Vascular headache/ Sinus headache	2335 (8.11)
Hyperpyrexia/pyrexia/ Hyperthermia	2042 (7.09)
Fatigue	1492 (5.18)
Nausea	1268 (4.40)
Chills	1208 (4.19)
Myalgia/ Musculoskeletal pain	1127 (3.91)
Dizziness/ exertional/ postural	832 (2.89)
Arthralgia/ Arthritis/ Arthropathy/ Osteoarthritis	731 (2.54)
Pain in extremity	570 (1.98)
Pain	555 (1.93)
Vaccination site/Injection site/Administration site pain	542 (1.88)
Dyspnoea/ at rest/ exertional	497 (1.73)
Vomiting/ Vomiting projectile	447 (1.55)
Malaise	444 (1.54)
Rash/ Rash erythematous/ macular/ maculopapular/ morbilliform/ popular/ pruritic/ vesicular/ Vasculitic rash	380 (1.32)

Table 4: Distribution of serious and non-serious Adverse Events as per the vaccine, gender and age groups.

		Serious	Non-Serious	Total
Vaccine Name (N = 103954)	BNT162b2(Pfizer)	21384 (25.23)	63357 (74.77)	84741
	AstraZeneca	5649 (45.15)	6861 (54.84)	12510
	Moderna	1697 (26.73)	4650 (73.27)	6347
	Covid-19 vaccine (Vero cell), inactivated	9 (28.12)	23 (71.87)	32
	Covaxin	0	2 (100)	2
	No vaccine name mentioned	60 (18.7)	261 (81.30)	321
Gender (N = 103954)	Male	5361 (29.30)	12935 (70.70)	18296
	Female	22866 (27.41)	60551 (72.59)	83417
	Gender not reported	572 (25.52)	1669 (74.48)	2241
Age Group (N = 103954)	< 18 Years	265 (31.29)	582 (68.71)	847
	18 – 64 Years	23255 (25.98)	66250 (74.02)	89505
	>65 Years	4077 (53.32)	3570 (46.68)	7647
	Unknown	1202 (20.18)	4753 (79.82)	5955

Values in parenthesis are percentages. N= total adverse events

Table 5: Distribution of events of death as per the vaccine, age and gender (N = 103954).

		Death (%)
Vaccine Name	BNT162b2 (N=84741)	337 (0.40)
	AstraZeneca (N = 12510)	9 (0.07)
	Moderna (N = 6347)	78 (1.23)
Gender	Male (N = 18296)	205 (1.12)
	Female (N = 83417)	213 (0.25)
	Gender not reported (N=2241)	6 (0.27)
Age Group	< 18 Years (N=847)	3 (0.35)
	18 – 64 Years (N=89505)	43 (0.05)
	>65 Years (N = 7647)	342 (4.47)
	Unknown (N = 5955)	36 (0.6)

Figures

Figure 1: Schematic Diagram of assessment of Adverse Events associated with COVID-19 vaccines in VigiBase database




Figure 2: Distribution of Serious Adverse Events reported in VigiBase associated with COVID-19 vaccines across continents

